华润三九医药股份有限公司 关于向银行申请并购贷款的公告

Group 1 - The core point of the announcement is that China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. plans to apply for a merger loan to acquire a 28% stake in Tianjin Tasly Pharmaceutical Group Co., Ltd. [1][2] - The company intends to apply for a merger loan not exceeding RMB 35.90 billion, with a loan term of up to 10 years [2][3]. - The loan will be used to pay or replace part of the acquisition payment, and the company will cooperate with no more than 10 banks [3][4]. Group 2 - The application for the merger loan is based on the company's medium to long-term development plan, considering financing terms, structure, and efficiency [5]. - The company currently has a good operating status and repayment ability, and the loan will not pose significant financial risks [5]. - The transaction has been approved by the company's board of directors and supervisory board [1][6].